Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kezar Life Sciences Inc (DE:2KZ)
MUNICH:2KZ
RESEARCH TOOLSreports
Kezar Life Sciences (2KZ) Stock Price & Analysis
0 Followers
2KZ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.62 - €2.80
Previous Close€0.72
Volume0.00
Average Volume (3M)13.57K
Market Cap
€54.72M
Enterprise Value-€115.67M
Total Cash (Recent Filing)$201.37M
Total Debt (Recent Filing)$18.93M
Price to Earnings (P/E)N/A
Beta0.93
Next Earnings
May 09, 2024EPS Estimate
-€0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume13,566
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-16.52
Enterprise Value/Gross Profit-16.52
Enterprise Value/Ebitda1.10
Forecast
1Y Price Target
€18.68Price Target Upside2494.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Kezar Life Sciences News
Bulls Say, Bears Say
Bulls Say
Financial StabilityKezar has a cash runway into 2026E, indicating financial stability.
Market ExpansionKezar announced an exclusive licensing agreement to develop and commercialize zeto in several Asian markets.
Product PotentialZetomipzomib could be a differentiated therapeutic option with a first-in-class mechanism.
Bears Say
Clinical DevelopmentRisks include potential negative data releases and failure to advance zetomipzomib in a timely manner.
Clinical TrialsRisks include, but are not limited to: negative data releases from future PALIZADE trial updates for zetomipzomib; failure to advance zetomipzomib into pivotal development in LN in a timely fashion.
EarningsKZR reported a Q4 net loss of $32MM.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
2KZ FAQ
What was Kezar Life Sciences Inc’s price range in the past 12 months?
Kezar Life Sciences Inc lowest stock price was €0.61 and its highest was €2.80 in the past 12 months.
What is Kezar Life Sciences Inc’s market cap?
Currently, no data Available
When is Kezar Life Sciences Inc’s upcoming earnings report date?
Kezar Life Sciences Inc’s upcoming earnings report date is May 09, 2024 which is in 11 days.
How were Kezar Life Sciences Inc’s earnings last quarter?
Kezar Life Sciences Inc released its earnings results on Mar 14, 2024. The company reported -€0.411 earnings per share for the quarter, missing the consensus estimate of -€0.355 by -€0.056.
Is Kezar Life Sciences Inc overvalued?
According to Wall Street analysts Kezar Life Sciences Inc’s price is currently Undervalued.
Does Kezar Life Sciences Inc pay dividends?
Kezar Life Sciences Inc does not currently pay dividends.
What is Kezar Life Sciences Inc’s EPS estimate?
Kezar Life Sciences Inc’s EPS estimate is -€0.31.
How many shares outstanding does Kezar Life Sciences Inc have?
Currently, no data Available
What happened to Kezar Life Sciences Inc’s price movement after its last earnings report?
Kezar Life Sciences Inc reported an EPS of -€0.411 in its last earnings report, missing expectations of -€0.355. Following the earnings report the stock price went down -13.529%.
Which hedge fund is a major shareholder of Kezar Life Sciences Inc?
Among the largest hedge funds holding Kezar Life Sciences Inc’s share is Wexford Capital LP. It holds Kezar Life Sciences Inc’s shares valued at 22K.
---
Kezar Life Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€18.68 (2494.22% Upside)
€18.68 (2494.22% Upside)
Blogger Sentiment
Bullish
DE:2KZ Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.75%
12-Months-Change
Fundamentals
Return on Equity
-44.54%
Trailing 12-Months
Asset Growth
-26.15%
Trailing 12-Months
Company Description
Kezar Life Sciences Inc
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
---
2KZ Stock 12 Months Forecast
Average Price Target
€18.68
▲(2494.22% Upside)
Technical Analysis
Kezar Life Sciences
―
Arcturus Therapeutics
―
Crinetics Pharmaceuticals
―
Kodiak Sciences
―
RegenXBio
―
Best Analysts Covering 2KZ
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-17.98%
reiterated a buy rating last month
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -17.98% per trade.
---